canagliflozin
Selected indexed studies
- Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program. (Circulation, 2018) [PMID:29526832]
- Canagliflozin Mitigates Diabetic Cardiomyopathy through Enhanced PINK1-Parkin Mitophagy. (Int J Mol Sci, 2024) [PMID:39000117]
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. (N Engl J Med, 2017) [PMID:29166232]
_Worker-drafted node — pending editorial review._
Connections
canagliflozin is a side effect of
Sources
- Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program. (2018) pubmed
- Canagliflozin Mitigates Diabetic Cardiomyopathy through Enhanced PINK1-Parkin Mitophagy. (2024) pubmed
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. (2017) pubmed
- Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. (2018) pubmed
- Canagliflozin and Amputation Risk: Evidence So Far. (2020) pubmed
- Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial. (2020) pubmed
- Canagliflozin impairs T cell effector function via metabolic suppression in autoimmunity. (2023) pubmed
- Canagliflozin: A Review in Type 2 Diabetes. (2017) pubmed
- Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. (2019) pubmed
- Repurposing Canagliflozin to target brain aging. (2023) pubmed